87 related articles for article (PubMed ID: 12436438)
61. Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects.
Veltri S; Smith JW
Stem Cells; 1996 Mar; 14(2):164-76. PubMed ID: 8991536
[TBL] [Abstract][Full Text] [Related]
62. Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials.
Atkins MB; Dutcher J; Weiss G; Margolin K; Clark J; Sosman J; Logan T; Aronson F; Mier J;
Med Oncol; 2001; 18(3):197-207. PubMed ID: 11917944
[TBL] [Abstract][Full Text] [Related]
63. Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma.
Mani S; Poo WJ
Am J Clin Oncol; 1996 Apr; 19(2):149-53. PubMed ID: 8610639
[TBL] [Abstract][Full Text] [Related]
64. A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer.
Baaten G; Voogd AC; Wagstaff J
Eur J Cancer; 2004 May; 40(8):1127-44. PubMed ID: 15110876
[TBL] [Abstract][Full Text] [Related]
65. [Regional immunotherapy of metastatic renal cell carcinoma].
Heinzer H; Huland E; Huland H
Urologe A; 2002 May; 41(3):239-48. PubMed ID: 12132273
[TBL] [Abstract][Full Text] [Related]
66. Medical treatment of advanced renal cell carcinoma: present options and future directions.
Canobbio L; Miglietta L; Boccardo F
Cancer Treat Rev; 1996 Mar; 22(2):85-104. PubMed ID: 8665566
[TBL] [Abstract][Full Text] [Related]
67. Application of IL-2 and other cytokines in renal cancer.
McDermott DF; Atkins MB
Expert Opin Biol Ther; 2004 Apr; 4(4):455-68. PubMed ID: 15102596
[TBL] [Abstract][Full Text] [Related]
68. Elicitation of health state utilities in metastatic renal cell carcinoma.
Swinburn P; Lloyd A; Nathan P; Choueiri TK; Cella D; Neary MP
Curr Med Res Opin; 2010 May; 26(5):1091-6. PubMed ID: 20225993
[TBL] [Abstract][Full Text] [Related]
69. Managing toxicities of high-dose interleukin-2.
Schwartz RN; Stover L; Dutcher JP
Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):11-20. PubMed ID: 12469935
[TBL] [Abstract][Full Text] [Related]
70. The application of high-dose interleukin-2 for metastatic renal cell carcinoma.
McDermott DF
Med Oncol; 2009; 26 Suppl 1():13-7. PubMed ID: 19148594
[TBL] [Abstract][Full Text] [Related]
71. Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma.
Mani S; Todd M; Poo WJ
Am J Clin Oncol; 1996 Apr; 19(2):187-9. PubMed ID: 8610647
[TBL] [Abstract][Full Text] [Related]
72. Renal cell carcinoma and interferon at the millennium.
Pastore RD; Pfeffer LM; Nanus DM
Cancer Invest; 2001; 19(3):281-91. PubMed ID: 11338886
[No Abstract] [Full Text] [Related]
73. Ingested type I interferon: a potential treatment for autoimmunity.
Brod SA
J Interferon Cytokine Res; 2002 Dec; 22(12):1153-66. PubMed ID: 12581487
[TBL] [Abstract][Full Text] [Related]
74. Toxicity management in patients receiving low-dose aldesleukin therapy.
Sundin DJ; Wolin MJ
Ann Pharmacother; 1998 Dec; 32(12):1344-52. PubMed ID: 9876817
[TBL] [Abstract][Full Text] [Related]
75. Case report and brief review: IL-2-induced myocarditis.
Eisner RM; Husain A; Clark JI
Cancer Invest; 2004; 22(3):401-4. PubMed ID: 15493361
[TBL] [Abstract][Full Text] [Related]
76. [Interferon induced psoriatic arthritis in a patient with renal cancer].
Gaál J; Kálmánchey J; Szegedi A; Szabó B; Surányi P
Orv Hetil; 2005 Dec; 146(49):2503-6. PubMed ID: 16398316
[TBL] [Abstract][Full Text] [Related]
77. Gastrointestinal perforations associated with interleukin-2 administration.
Heimann DM; Schwartzentruber DJ
J Immunother; 2004; 27(3):254-8. PubMed ID: 15076143
[TBL] [Abstract][Full Text] [Related]
78. Clinical research priorities in renal cell carcinoma: renal cell carcinoma chemoprevention strategies including target populations, proposed agents, and clinical trial designs--Workgroup No. 6. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).
Hanash KA; Aquilina JW; Barrett DM; Blute ML; Cockett AT; Corica FA; Hillman GG; Zbar B; Zhuang Z
Cancer; 1997 Sep; 80(5):999-1001. PubMed ID: 9307208
[No Abstract] [Full Text] [Related]
79. [Suicidal attempts in three postoperative patients with renal cancer after alpha interferon withdrawal].
Koseki K; Nakano M; Takaiwa M; Kamata T; Yosida J
Nihon Hinyokika Gakkai Zasshi; 2000 Jan; 91(1):29-32. PubMed ID: 10689880
[TBL] [Abstract][Full Text] [Related]
80. [Renal effects of recombinant interleukin-2].
Beloosesky Y; Engelstein D; Boner G
Harefuah; 1991 Apr; 120(7):386-8. PubMed ID: 1879788
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
